Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Lipopolysaccharide (LPS) O-antigen is the outermost component of the Gram-negative bacterium Pseudomonas aeruginosa, extending from the cell surface into the external environment. It consists of repeating polysaccharide units that are highly variable, defining the various serotypes of the species and playing a crucial role in bacterial survival within the host. The O-antigen serves as a protective shield against the host's innate immune system, specifically preventing the assembly of the complement membrane attack complex and resisting opsonization. In clinical medicine, it is a major target for the development of passive immunotherapies, such as monoclonal antibodies, and active vaccines intended to treat or prevent multidrug-resistant infections. However, the high degree of structural diversity among strains and the tendency of P. aeruginosa to lose its O-antigen during chronic infections (transitioning to a 'rough' phenotype) pose significant challenges for universal therapeutic targeting.
Monoclonal antibodies targeting the O-antigen promote opsonophagocytic killing by host immune cells and neutralize the endotoxic effects of LPS. Some antibiotics and antimicrobial peptides interact with the LPS layer to disrupt the outer membrane integrity, leading to cell lysis. Vaccines aim to induce long-term humoral immunity by generating antibodies specific to the O-antigen serotypes.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide O-antigen (Pseudomonas aeruginosa) (LPS O-antigen).